Skip to main content

Table 2 The main clinicopathologic features of patients and their distribution in the eligible studies

From: Prognostic value of Kindlin-2 expression in patients with solid tumors: a meta-analysis

Study (Author and year)

n

Age (years or numbers): [mean or median (range)] (cut-off: low/high)

Sex (M/F)

Histological differentiation (I/II/III)

Tumor size (cm) (cut-off) (low/high)

Tumor category (grade)

Lymphatic invasion (∓)

Vascular invasion (low/high)

Metastasis (∓)

Staging method

Stage (cut-off)

Other therapy (no/yes)

Yoshida et al. 2017 (I) [14]

79

65 (mean) (41–85) (65):39/40

51/28

9/63/7

NR

NR

19/60

32/47

NR

NR

NR

C: 9/70

R: 68/11

Zhan et al. 2015 [15]

31

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

NR

Mahawithitwong et al. 2013 [16]

95

65 (mean) (36–86)

(65): 52/43

58/37

10/33/52

NR

(T1/2/3/4) 9/3/82/1

34/61*

38/57

NR

UICC

NR

C: 10/85

R: 78/17

Cao et al. 2015 (II) [17]

110

(58): 55/55

80/30

33/67/10

(3, 5) 32/45/11

(T1, 2/3, 4) 7/103

57/53

NR

NR

TNM

(IIB/IIIA) 59/51

99/12

Cao et al. 2015 (III)[17]

147

(58): 79/68

113/34

23/109/15

(3, 5) 38/71/36

(T1, 2/3, 4) 20/127

64/83

NR

NR

TNM

(IIB/IIIA) 70/77

104/43

Wu et al. 2017 [18]

203

(65): 109/94

165/38

(Low/high) 96/107*

(3) 140/63

NR

NR

NR

NR

TNM

(I/II) 8/115*

NR

Papachristou et al. 2008 [19]

60

54 (mean) (21–85)

34/26

20/29/11*

(8) 23/37

NR

NR

NR

NR

NR

NR

NR

Ge et al. 2015 [20]

72

(53): 35/37

60/12

NR

(5) 29/43*

NR

NR

Cap: 44/28*

Mic: 49/23*

NR

TNM

(II/III) 41/31

NR

Lin et al. 2017 [21]

127

(60): 111/16

17/110

NR

(3) 10/117

NR

NR

Cap: 40/87

Mic: 66/61*

9/115*

NR

(II/III) 11/116

NR

Ning et al. 2017 [22]

100

(18): 40/60

68/32

(Low/high) 15/85*

NR

NR

NR

NR

60/40*

NR

NR

RC: 50/50*

Ou et al. 2016 [23]

188

39 (mean)

(39): 98/90*

103/85

NR

NR

NR

NR

NR

NR

NR

(II/III) 85/103*

NR

Ren et al. 2014 [24]

113

(50): 28/85*

−/113

(Low/high)

26/87*

NR

NR

NR

NR

49/34

FIGO

(I/II/III/IV) 9/13/73/10

RC: 21/68

Shen et al. 2012 [25]

40

67 (mean) (47–93)

(60): 14/26

30/10

4/8/28

NR

(T1, 2/3, 4) 8/32*

N1/2/3 21/10/9*

NR

37/3

Pathologic

(II/III) 8/32*

NR

Li et al. 2017 [26]

109

(60):62/47

67/42

36/41/32*

NR

(Tx/1/2/34) 4/68/20/17

Nx/0/1 2/99/8*

NR

NR

AJCC

(II/III) 70/39

NR

Yan et al. 2016 [27]

336

(65):177/159

240/96

NR

(4) 176/160

(T1, 2/3, 4) 167/169

202/134

NR

269/67*

TNM

(II/III) 124/212*

NR

  1. (I) This article (Yoshida [14]) was listed two cohort study because the sample types contains cancer tissue and startle cell. (II) and (III) This article (Cao [17]) included patients from generation dataset (II) and validation dataset (III)
  2. n: number of patients; NR: no report; Cap: capillary invasion; Mic: microvascular invasion; C: chemotherapy; R: radiotherapy; RC: response for chemotherapy
  3. *Means that Kindlin-2 expression was reported to have a significant relation with the variable in the study